Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Open Label, Dose Escalation, Dose Optimization, and Cohort Expansion Study of MGC030 in Participants With Advanced Solid Tumors

NCT07822399 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT07822399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07822399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Open Label, Dose Escalation, Dose Optimization, and Cohort Expansion Study of MGC030 in Participants With Advanced Solid Tumors
Lead sponsor
MacroGenics
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
March 31, 2029
Enrollment
314 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, esophageal cancer, gastric cancer (gc), gastroesophageal cancer, pancreatic cancer, urothelial cancer